Related Experiment Video

Updated: Aug 26, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Interaction at clinical level between erythrocyte acid phosphatase and adenosine deaminase genetic polymorphisms

F Gloria-Bottini1, P Lucarelli, A Amante

  • 1Division of Biometry and Human Development, 2nd University of Rome, School of Medicine, Italy.

Human Genetics
|June 1, 1989
PubMed

Insights

The study reveals that the impact of the red blood cell enzyme acid phosphatase type 1 (ACP1) on infant health outcomes, including birth weight and jaundice, is influenced by adenosine deaminase (ADA) genotype. This suggests a genetic link between these two enzyme systems.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • The red blood cell enzyme acid phosphatase type 1 (ACP1) and adenosine deaminase (ADA) are crucial in metabolic pathways.
  • Previous in vitro studies have indicated biochemical interactions between ACP1 and ADA systems.
  • The clinical relevance of these interactions, particularly in early life, remains to be fully elucidated.

Purpose of the Study:

  • To investigate the influence of ACP1 phenotype on key pediatric health indicators: birth weight, neonatal jaundice, and childhood obesity.
  • To determine if the effects of ACP1 are modulated by the genetic variations in the ADA genotype.
  • To explore the potential clinical implications of observed in vitro biochemical interactions between ACP1 and ADA.

Main Methods:

  • Retrospective analysis of pediatric patient data, correlating ACP1 phenotype and ADA genotype with birth weight, neonatal jaundice severity, and obesity status.
  • Statistical methods employed to assess the dependency of ACP1 effects on ADA genotype.
  • Comparison of clinical findings with established in vitro biochemical data on ACP1-ADA interactions.

Main Results:

  • A significant dependency was observed between ACP1 phenotype and birth weight, neonatal jaundice, and obesity in children, specifically linked to ADA genotype.
  • The presence of certain ADA genotypes modifies the phenotypic expression of ACP1 concerning these health outcomes.
  • These findings provide a clinical parallel to the previously reported in vitro biochemical interactions between the two enzyme systems.

Conclusions:

  • The interplay between ACP1 phenotype and ADA genotype significantly influences critical early-life health parameters in children.
  • These results highlight the importance of considering combined genetic factors for understanding complex pediatric conditions.
  • The study supports the hypothesis that observed in vitro biochemical interactions between ACP1 and ADA have tangible clinical consequences.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme04:17

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme

Published on: September 27, 2024

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...